QuiaPEG

Newsroom

Page:
123456
Oct 14, 2018

The Extraordinary General Meeting of QuiaPEG Pharmaceuticals Holding AB (publ) ("the Company") decided on 29thJune 2018 to establish a warrant-based incentive program for senior executives within the QuiaPEG Group through the issue of up to 1,000,000 warrants with the right to subscribe for new shares in the Company, and approval of the transfer of such options. The warrants could only be subscribed to by the company's wholly owned subsidiary, QuiaPEG Pharmaceuticals AB ("Subsidiary"), that has the entitlement and obligation to transfer the warrants to senior executives within the QuiaPEG Group on one or more occasions in accordance with the allocation decided by the Board.

Oct 12, 2018

QuiaPEG Pharmaceuticals Holding AB (publ), which develops improved and patentable versions of clinically validated or approved drugs using the company's unique technology platform, announces that, on October 10th, 2018, Steen Krøyer, Chairman of the Board, has acquired 75,000 shares at an average price of SEK 3.18, totaling SEK 238,500.

Oct 10, 2018

QuiaPEG Pharmaceuticals Holding AB (publ) receives so-called "Notice of Allowance" for granting of a patent in the United States.

Sept 27, 2018

QuiaPEG continues the commercialization of avUni-Qleaver® together with Sinopeg by exhibiting in Sinopeg's booth at the major trade fair CPHI in madrid, 9-11 october.

Page:
123456
Contact
QuiaPEG Pharmaceuticals Holding AB

Virdings Allé 32 B
754 54 Uppsala
Sweden
+46 (0) 70 693 12 53
info@quiapeg.com

User terms & privacy policy
Send a message